Home Stock

Stock Research: Genmab

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Genmab

CPH:GMAB DK0010272202
100
  • Value
    36
  • Growth
    85
  • Safety
    Safety
    75
  • Combined
    93
  • Sentiment
    93
  • 360° View
    360° View
    100
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Genmab A/S is a biotechnology company specializing in antibody therapeutics for cancer treatment. The company operates in the biotechnology industry and creates antibody therapeutics such as DARZALEX, Kesimpta, TEPEZZA, and FASPRO. Genmab operates internationally, with its approved therapies available in various regions. In the last fiscal year, the company had a market cap of $14,027 million, profits of $2,979 million, revenue of $3,122 million, and 2682 employees.

more

ANALYSIS: With an Obermatt 360° View of 96 (better than 96% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Genmab are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Genmab. The consolidated Growth Rank has a good rank of 79, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 79% of competitors in the same industry. The consolidated Safety Rank at 75 means that the company has a financing structure that is safer than 75% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 67, which means that professional investors are more optimistic about the stock than for 67% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 36, meaning that the share price of Genmab is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 64% of alternative stocks in the same industry. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank 360° View
Country Denmark
Industry Biotechnology
Size Large
Website genmab.com
Index
OMX C20
NASDAQ
Genmab stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 8-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
36 18 3 1
Growth
85 42 57 51
Safety
Safety
75 100 98 90
Sentiment
93 48 56 52
360° View
360° View
100 56 51 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
41 31 36 39
Opinions Change
80 60 74 53
Pro Holdings
n/a 65 65 68
Market Pulse
71 54 43 41
Sentiment
93 48 56 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
36 18 3 1
Growth
85 42 57 51
Safety Safety
75 100 98 90
Combined
93 72 58 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
62 11 9 3
Price vs. Earnings (P/E)
21 47 17 10
Price vs. Book (P/B)
44 42 19 8
Dividend Yield
1 1 1 1
Value
36 18 3 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
55 83 75 82
Profit Growth
94 21 28 8
Capital Growth
52 67 88 83
Stock Returns
54 18 22 32
Growth
85 42 57 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
28 90 92 89
Refinancing
74 58 71 56
Liquidity
77 92 94 98
Safety Safety
75 100 98 90

Similar Stocks

Discover high‑ranked alternatives to Genmab and broaden your portfolio horizons.

Strabag

VIE:STR
Country: Austria
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

Yara International

OSL:YAR
Country: Norway
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Polski Koncern Naftowy ORLEN Spolka Akcyjna

WSE:PKN
Country: Poland
Industry: Oil & Gas Refining
Size: XX-Large
Full Stock Analysis

Bachem

SWX:BANB
Country: Switzerland
Industry: Life Sciences Tools & Services
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews